Eli Lilly's Psychedelic Power: $3.8 Billion Mega Deal for ATAI

AtaiBeckley (NASDAQ:ATAI) surged 33.4% on the back of a $3.8 billion acquisition by Eli Lilly (NYSE:LLY), closing at $7.15 with trading volume spiking 1,494% above its three-month average to 164.9 million shares. The deal structure—$6.75 in cash and $2.50 in contingent value rights (CVRs)—reflects market optimism around ATAI's DMT and psychedelic treatments for depression, anxiety, and opioid use disorder, particularly amid the Trump administration's favorable stance on such therapies. While peers like COMPASS Pathways (NASDAQ:CMPS) fell 6.61%, the broader psychedelics sector remains tethered to ATAI's milestone-driven CVRs. Despite a 64% post-IPO decline, the stock's doubling over the past year underscores speculative momentum. Meanwhile, the S&P 500 (-0.50%) and Nasdaq (-1.47%) hinted at cautious market sentiment. Investors are reminded that Stock Advisor's top 10 stock picks, with a history of outperforming the S&P 500 by 4x, may offer more sustainable long-term opportunities than ATAI's volatile trajectory.